Organogenesis Holdings Inc. withdraws earnings guidance for the the 2023. The company is withdrawing its previously announced fiscal year 2023 guidance, originally issued on May 10, 2023, due to the uncertainty resulting from the potential impact of the recently published local coverage determinations from Novitas, First Coast Services and CGS to limit coverage for treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to include only Apligraf and Dermagraft. The Company is currently unable to predict the impact that the recently published local coverage determinations will have on its financial position and operating results.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.775 USD | +0.18% | -2.46% | -32.15% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.15% | 367M | |
+43.81% | 54.04B | |
+43.57% | 41.96B | |
-1.37% | 41.92B | |
-7.59% | 28.35B | |
+12.12% | 26.35B | |
-22.16% | 19B | |
+7.34% | 13B | |
+29.26% | 12.28B | |
+25.68% | 12.19B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023